Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO   US0535881090

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

06/25/2013 | 05:25pm US/Eastern

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
info@rigrodskylong.com
http://www.rigrodskylong.com


© Business Wire 2013
React to this article
Latest news on AVEO PHARMACEUTICALS, INC.
11/11 AVEO PHARMACEUTICALS : Enters into Research and Exclusive Option Agreement with ..
11/05 AVEO PHARMACEUTICALS : Oncology : Reports Third Quarter 2014 Financial Results
10/28 AVEO PHARMACEUTICALS : Assigned Patent
09/29 AVEO PHARMACEUTICALS : Oncology : Announces Results from Phase 2 Clinical Studie..
09/29 AVEO PHARMACEUTICALS : and Biodesix Announce Exploratory Analysis of VeriStrat-S..
09/26 AVEO PHARMACEUTICALS : Oncology : Announces Presentation of AV-380 Preclinical D..
09/26 AVEO PHARMACEUTICALS : Entry into a Material Definitive Agreement, Termination o..
09/26 AVEO PHARMACEUTICALS : Oncology : Announces Lease Termination and Amendment to D..
09/17 AVEO PHARMACEUTICALS : Clinical Data on AVEO Oncology’s Ficlatuzumab and T..
08/11 AVEO PHARMACEUTICALS : Oncology : Reports Second Quarter 2014 Financial Results ..
Advertisement
Chart
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF